Applied Biosystems transfers interest in Celera Diagnostics to Celera Genomics.
ByAinvest
Friday, May 23, 2025 12:10 pm ET1min read
APLT--
The move comes as Celera Diagnostics, previously known as Celera Genomics, expands its diagnostics portfolio. Applied Biosystems, a leading provider of life science tools and services, will retain its position in the market while Celera Genomics gains access to additional resources and expertise.
The deal reflects the growing importance of clinical diagnostics and the need for innovative solutions in the sector. By combining forces, the two companies aim to enhance their offerings and better serve their respective markets.
For investors, this transaction signifies a strategic shift in the diagnostics landscape. Applied Biosystems' focus on research and clinical diagnostics instrumentation will remain unchanged, while Celera Genomics benefits from the expanded capabilities and market reach.
The transfer of interest is a significant development in the life sciences industry, highlighting the importance of strategic partnerships and acquisitions in driving innovation and growth.
References:
[1] https://www.selectscience.net/article/thermo-fisher-scientific-introduces-fast-automated-plasmid-dna-purification-kit
[2] https://www.morningstar.com/news/business-wire/20250519067489/apreo-health-announces-presentation-of-clinical-data-from-the-breathe-12-trials-at-ats-2025-and-publication-of-six-month-data-in-american-journal-of-respiratory-and-critical-care-medicine
Applied Biosystems has transferred its 50% interest in Celera Diagnostics to Celera Genomics in exchange for various considerations and cash. As part of the deal, Applied Biosystems will serve the end-user clinical diagnostics instrumentation market as well as research markets.
Applied Biosystems has announced the transfer of its 50% interest in Celera Diagnostics to Celera Genomics. The transaction, finalized on May 24, 2025, includes various considerations and cash payments. As part of the agreement, Applied Biosystems will continue to serve the end-user clinical diagnostics instrumentation market and research markets.The move comes as Celera Diagnostics, previously known as Celera Genomics, expands its diagnostics portfolio. Applied Biosystems, a leading provider of life science tools and services, will retain its position in the market while Celera Genomics gains access to additional resources and expertise.
The deal reflects the growing importance of clinical diagnostics and the need for innovative solutions in the sector. By combining forces, the two companies aim to enhance their offerings and better serve their respective markets.
For investors, this transaction signifies a strategic shift in the diagnostics landscape. Applied Biosystems' focus on research and clinical diagnostics instrumentation will remain unchanged, while Celera Genomics benefits from the expanded capabilities and market reach.
The transfer of interest is a significant development in the life sciences industry, highlighting the importance of strategic partnerships and acquisitions in driving innovation and growth.
References:
[1] https://www.selectscience.net/article/thermo-fisher-scientific-introduces-fast-automated-plasmid-dna-purification-kit
[2] https://www.morningstar.com/news/business-wire/20250519067489/apreo-health-announces-presentation-of-clinical-data-from-the-breathe-12-trials-at-ats-2025-and-publication-of-six-month-data-in-american-journal-of-respiratory-and-critical-care-medicine
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet